Ticker
AKRO

Price
17.76
Stock movement down
-2.48 (-12.25%)
Company name
Akero Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
834.20M
Ent value
614.44M
Price/Sales
-
Price/Book
2.55
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-62.97%
3 year return
-15.51%
5 year return
-
10 year return
-
Last updated: 2024-02-06

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

AKRO does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book2.55
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count46.97M
EPS (TTM)-4.24
FCF per share (TTM)-3.46

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)115.16M
Operating income (TTM)-168.80M
Net income (TTM)-165.47M
EPS (TTM)-4.24
EPS (1y forward)-3.47

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash249.77M
Net receivables0.00
Total current assets355.17M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets356.57M
Accounts payable7.97M
Short/Current long term debt1.08M
Total current liabilities19.08M
Total liabilities30.01M
Shareholder's equity326.56M
Net tangible assets326.56M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-134.90M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-134.90M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-50.67%
Return on Assets-46.40%
Return on Invested Capital-49.23%
Cash Return on Invested Capital-40.14%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open16.98
Daily high18.39
Daily low15.32
Daily Volume4.41M
All-time high56.88
1y analyst estimate57.50
Beta-0.91
EPS (TTM)-4.24
Dividend per share-
Ex-div date-
Next earnings date15 Mar 2024

Downside potential

Loading...
Downside potential data
AKROS&P500
Current price drop from All-time high-68.78%-0.07%
Highest price drop-79.99%-56.47%
Date of highest drop27 Oct 20239 Mar 2009
Avg drop from high-33.37%-11.41%
Avg time to new high35 days13 days
Max time to new high571 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
AKRO (Akero Therapeutics Inc) company logo
Marketcap
834.20M
Marketcap category
Small-cap
Description
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Employees
38
Investor relations
-
SEC filings
CEO
Andrew Cheng
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...